{"id":"W2559341198","doi":"10.1007/s00277-016-2878-5","title":"Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone","year":2016,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Pharmacyclics; Genentech; H. Lundbeck A/S; Baxalta; Celgene; Gilead Sciences; Servier; Astellas Pharma; TG Therapeutics; Amgen; Pfizer; F. Hoffmann-La Roche; Roche","keywords":"Medicine; Bendamustine; Rituximab; Obinutuzumab; Internal medicine; Follicular lymphoma; Quality of life (healthcare); Lymphoma; Refractory (planetary science); Oncology; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001799273,0.000471096,0.001297361,0.0002472303,0.0001962884,0.0005509859,0.0003644537,0.0004876672,0.000826961],"category_scores_gemma":[0.001262732,0.000274287,0.001265086,0.0003174946,0.0004051215,0.0003605505,0.0002647381,0.0009356139,0.0001322543],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004994867,"about_ca_system_score_gemma":0.0004694978,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006606259,"about_ca_topic_score_gemma":0.0016968,"domain_scores_codex":[0.999403,0.0003852003,0.00004601865,0.00004721142,0.00004812752,0.00007042549],"domain_scores_gemma":[0.999153,0.0002499001,0.000252882,0.00004872483,0.00003938939,0.0002560328],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8463714,0.01202221,0.07290389,0.0006144526,0.004240896,0.0001194312,0.0002081973,0.001194285,0.008245713,0.00007142061,0.0007804587,0.05322776],"study_design_scores_gemma":[0.328694,0.3914796,0.2702998,0.0000833177,0.003943997,0.0002275527,0.0001605988,0.001616724,0.001572345,0.0001611365,0.00172189,0.00003904236],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978427,0.00158803,0.00005667816,0.00006814709,0.00002199948,0.0001204406,0.000122344,0.000003276595,0.0001764557],"genre_scores_gemma":[0.9984335,0.0005813655,0.0001639104,0.0001702623,0.00004637455,0.0001597188,0.0002844163,0.000001725294,0.000158633],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001799273,"threshold_uncertainty_score":0.009515584,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0440020925305904,"score_gpt":0.3413790804974494,"score_spread":0.297376987966859,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}